• Chart
  • Rating
  • Financials
  • Technicals
  • Volume
  • Result
  • Synopsis
  • Corp Action
  • MF Shareholding
  • Similar Stocks
  • FAQs
    1. Home
    2. Stocks
    3. Natcopharm Share Price

    Natco Pharma Share PriceNatco Pharma

    Mid Cap 11.8k Result
    ₹780.25
    6.2 (0.8%)
    As on 29 November, 2023 | 16:25 BSE: 524816 NSE: NATCOPHARMISIN: INE987B01026

    Natco Pharma Performance

    Day Range

    • Low 772.1
    • High 786.95
    780.25

    52 Week Range

    • Low 502
    • High 928
    780.25
    • Open Price777.9
    • Previous Close774.05
    • Volume801640

    Start SIP in Natco Pharma

    Start SIP

    Natco Pharma Share Price

    • Over 1 Month -3.15%
    • Over 3 Month -12.9%
    • Over 6 Month 23.89%
    • Over 1 Year 37.61%

    Natco Pharma Key Statistics

    P/E Ratio 12.4
    PEG Ratio 0.1
    Market Cap Cr 13,975
    Price to Book Ratio 2.9
    EPS 34.7
    Dividend 1.2
    Relative Strength Index 45.49
    Money Flow Index 48.71
    MACD Signal -12.18
    Average True Range 26.72

    Natco Pharma Investment Rating

    • Master Rating:

    • Natco Pharma has an operating revenue of Rs. 3,562.30 Cr. on a trailing 12-month basis. An annual revenue growth of 38% is outstanding, Pre-tax margin of 32% is great, ROE of 14% is good. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its 50DMA and around 10% up from its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. It is currently FORMING a base in its weekly chart and is trading around 16% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 77 which is a FAIR score but needs to improve its earnings, a RS Rating of 47 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B which is evident from recent demand for the stock, Group Rank of 76 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of B is close to being the best. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has mediocre earnings and technical strength, there are superior stocks in the current market environment.

    EPS Strength

    Price Strength

    Buyer Demand

    Group Rank

    Natco Pharma Financials
    IndicatorSep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022
    Oper Rev Qtr Cr 9311,048781413351806514
    Operating Expenses Qtr Cr 488545454346281426552
    Operating Profit Qtr Cr 4425043286870379-38
    Depreciation Qtr Cr 40403838383736
    Interest Qtr Cr 3313234
    Tax Qtr Cr 6470528965-6
    Net Profit Qtr Cr 3604052543738308-61
    IndicatorMar 2023Mar 2022
    Total Revenue Annual Cr 2,4371,862
    Operating Expenses Annual Cr 1,5061,555
    Operating Profit Annual in Cr 845213
    Depreciation Cr 151138
    Interest Annual Cr 913
    Tax Annual Cr 13417
    Net Profit Annual Cr 637139
    IndicatorMar 2023Mar 2022
    Cash from Operating Activity Annual Cr 78458
    Cash from Investing Activity Annual Cr -437-93
    Cash from Financing Annual Activity Cr -34736
    Net Cash Flow Annual Cr 11
    IndicatorMar 2023Mar 2022
    Total ShareHolders Funds Annual Cr 4,7024,192
    Fixed Assets Annual Cr 2,2972,303
    Total Non Current Assets Annual Cr 2,8932,800
    Total Current Assets Annual Cr 2,4952,178
    Total Assets Annual Cr 5,3884,978
    IndicatorMar 2023Mar 2022
    Book Value Per Share Annual Rs 258230
    ROE Annual % 143
    ROCE Annual % 164
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin % 4017
    IndicatorSep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022
    Oper Rev Qtr Cr 1,0311,141898493432885597
    Operating Expenses Qtr Cr 573613559387337489615
    Operating Profit Qtr Cr 45852833910695395-19
    Depreciation Qtr Cr 44444142424038
    Interest Qtr Cr 4434447
    Tax Qtr Cr 7180491914651
    Net Profit Qtr Cr 3694202766257320-51
    IndicatorMar 2023Mar 2022
    Total Revenue Annual Cr 2,8122,044
    Operating Expenses Annual Cr 1,7721,681
    Operating Profit Annual in Cr 936264
    Depreciation Cr 164143
    Interest Annual Cr 1518
    Tax Annual Cr 14732
    Net Profit Annual Cr 715170
    IndicatorMar 2023Mar 2022
    Cash from Operating Activity Annual Cr 84947
    Cash from Investing Activity Annual Cr -477-5
    Cash from Financing Annual Activity Cr -36335
    Net Cash Flow Annual Cr 976
    IndicatorMar 2023Mar 2022
    Total ShareHolders Funds Annual Cr 4,8744,264
    Fixed Assets Annual Cr 2,4362,391
    Total Non Current Assets Annual Cr 2,6572,612
    Total Current Assets Annual Cr 3,0002,497
    Total Assets Annual Cr 5,6575,109
    IndicatorMar 2023Mar 2022
    Book Value Per Share Annual Rs 267234
    ROE Annual % 154
    ROCE Annual % 185
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin % 3819
    Invest in Natco Pharma

    Natco Pharma Technicals

    EMA & SMA

    Current Price
    ₹780.25
    6.2 (0.8%)
    pointer
    • Bullish Moving Average
    • ___
    • 6
    • Bearish Moving Average
    • ___
    • 10
    • 20 Day
    • ₹782.43
    • 50 Day
    • ₹799.45
    • 100 Day
    • ₹785.64
    • 200 Day
    • ₹741.88
    • 20 Day
    • ₹768.32
    • 50 Day
    • ₹816.28
    • 100 Day
    • ₹816.81
    • 200 Day
    • ₹702.52

    Natco Pharma Resistance and Support

    PIVOT
    ₹777.65
    Resistance
    First Resistance ₹783.6
    Second Resistance ₹793.15
    Third Resistance ₹799.1
    RSI 45.49
    MFI 48.71
    MACD Single Line -12.18
    MACD -7.49
    Support
    First Resistance ₹768.1
    Second Resistance ₹762.15
    Third Resistance ₹752.6

    Natco Pharma Delivery and Volume

    Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
    Day 518,877 35,615,717 68.64
    Week 851,543 43,036,971 50.54
    1 Month 1,046,851 55,462,141 52.98
    6 Month 830,717 42,590,870 51.27

    Natco Pharma Result Highlights

    Natco Pharma Synopsis

    NSE-Medical-Diversified

    Natco Pharma is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 2351.00 Cr. and Equity Capital is Rs. 36.50 Cr. for the Year ended 31/03/2023. Natco Pharma Ltd. is a Public Limited Listed company incorporated on 19/09/1981 and has its registered office in the State of Telangana, India. Company’s Corporate Identification Number(CIN) is L24230TG1981PLC003201 and registration number is 003201.
    Market Cap 13,951
    Sales 3,173
    Shares in Float 8.96
    No of funds 269
    Yield 1.23
    Book Value 3
    U/D Vol ratio 0.9
    LTDebt / Equity
    Alpha 0.14
    Beta 0.27

    Natco Pharma

    Owner NameSep-23Jun-23Mar-23Dec-22
    Promoters 49.71%49.76%48.84%48.82%
    Mutual Funds 7.65%9.45%8.5%8.18%
    Insurance Companies 6.34%5.57%6.42%6.18%
    Foreign Portfolio Investors 12.82%11.03%11.91%11.73%
    Financial Institutions/ Banks
    Individual Investors 19.5%20.21%20.24%19.83%
    Others 3.98%3.98%4.09%5.26%

    Natco Pharma Management

    Name Designation
    Mr. V C Nannapaneni Managing Director
    Mr. Rajeev Nannapaneni Director & CEO
    Mr. T V Rao Independent Director
    Mr. G S Murthy Chairman & Ind.Director
    Mr. D G Prasad Independent Director
    Dr. M U R Naidu Independent Director
    Dr. Leela Digumarti Independent Director
    Mr. P S R K Prasad Director & Exe. VP (Corp. Engg. Services)
    Dr. Linga Rao Donthineni Director & President (Tech. Affairs)
    Mr. Pavan Bhat Director

    Natco Pharma Forecast

    Price Estimates

    2,000(9.8%)
    1,758(-3.5%)
    1,590(-12.7%)

    Other Analyst Rating

    Natco Pharma Corporate Action

    Date Purpose Remarks
    2023-11-14 Quarterly Results & Interim Dividend
    2023-08-09 Quarterly Results & Interim Dividend
    2023-05-29 Audited Results
    2023-03-08 Buy Back of shares
    2023-02-09 Quarterly Results & Interim Dividend
    Date Purpose Remarks
    2023-11-24 INTERIM Rs.1.25 per share(62.5%)Second Interim Dividend
    2023-08-22 INTERIM Rs.7.00 per share(350%)Interim Dividend
    2023-02-21 INTERIM Rs.1.25 per share (62.5%) Third Interim Dividend
    2022-11-22 INTERIM Re.0.75 per share (37.50%) Second Interim Dividend
    2022-08-22 INTERIM Rs.3.50 per share(175%)Interim Dividend

    Natco Pharma MF Shareholding

    Name Amount(cr)
    ICICI Prudential Value Discovery Fund Growth 32494
    Mirae Asset Emerging Bluechip Fund Growth 28104
    SBI Magnum Midcap Fund Regular Growth 13202
    ICICI Prudential India Opportunities Fund Regular Growth 12448
    Mirae Asset Midcap Fund Regular Growth 11784

    Natco Pharma FAQs

    What is Share Price of Natco Pharma ?

    Natco Pharma share price is ₹780 As on 29 November, 2023 | 16:11

    What is the Market Cap of Natco Pharma ?

    The Market Cap of Natco Pharma is ₹13975 Cr As on 29 November, 2023 | 16:11

    What is the P/E ratio of Natco Pharma ?

    The P/E ratio of Natco Pharma is 12.4 As on 29 November, 2023 | 16:11

    What is the PB ratio of Natco Pharma ?

    The PB ratio of Natco Pharma is 2.9 As on 29 November, 2023 | 16:11

    Q2FY23

    More Information

    CIN: L67190MH2007PLC289249 | Stock Broker SEBI Regn.: INZ000010231 | SEBI RA Regn.: INH000004680 | SEBI Depository Regn.: IN DP CDSL: IN-DP-192-2016 | AMFI REGN No.: ARN-104096 | NSE Member id: 14300 | BSE Member id: 6363 | MCX Member ID: 55945 | Investment Adviser Regn No: INA000014252 | Registered Address - IIFL House, Sun Infotech Park, Road no. 16V, Plot no. B-23, MIDC, Thane Industrial Area, Waghle Estate, Thane, Maharashtra - 400604

    *Brokerage will be levied flat fee/executed order basis and not on a percentage basis. Flat fee of Rs. 10/order is available with Power Investor & Ultra Trader Packs. Investment in securities market are subject to market risk, read all related documents carefully before investing. Digital account would be opened after all procedure relating to IPV and client due diligence is completed. If sale/ purchase value of share of Rs.10/- or less, a maximum brokerage of 25 paisa per share may be collected. Brokerage will not exceed the SEBI prescribed limit.

    Compliance Officer: Ms. Namita Godbole, Email: support@5paisa.com, Support desk helpline: 8976689766

    Contact Us

    Attention Investors

    • 1. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.
    • 2. Message from Exchange(s): Prevent Unauthorised transactions in your account --> Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day. Issued in the interest of investors.
    • 3. Message from Depositories: a) Prevent Unauthorized Transactions in your demat account --> Update your mobile number with your Depository Participant. Receive alerts on your registered mobile for all debit and other important transactions in your demat account directly from CDSL on the same day issued in the interest of investors. b) KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
    ©2023, 5Paisa Capital Ltd. All Rights Reserved.
    We are ISO 27001:2013 Certified.